Literature DB >> 25152591

Electrochemiluminescence immunoassay method underestimates cortisol suppression in ulcerative colitis patients treated with oral prednisone.

Francesco Manguso1, Raffaele Bennato1, Giovanni Lombardi1, Assunta Viola1, Elisabetta Riccio1, Livio Cipolletta1.   

Abstract

AIM: To evaluate cortisolemia by using conventional electrochemiluminescence immunoassay (ECLIA) method compared to liquid chromatography-tandem mass spectrometry (LC-MS/MS) method in active ulcerative colitis (UC) patients treated with oral prednisone (PD).
METHODS: Twenty patients (12 males) with acute relapse of UC started oral PD at a dose of 40 mg once a day, tapered of 10 mg every 2 wk. When a stable 2-wk daily dose of 30 mg was reached, blood samples for cortisol levels' measurement were drawn in the morning in fasting conditions to determine circulating cortisol by LC-MS/MS and ECLIA assay.
RESULTS: Median interquartile range cortisolemia with ECLIA and LC-MS/MS method was 54.1 (185.8) nmol/L and 32.1 (124.0) nmol/L, respectively (P < 0.001). The within-patient median differences between the two methods was 23.2 (40.6) nmol/L, with higher cortisol levels for the ECLIA method. The estimated geometric mean ratio between methods was 1.85 (95%CI: 2.39-1.43) considering all data or 1.58 (95%CI: 2.30-1.09) considering only data above the limit of quantification (n = 12). The 95%CIs of the geometric mean ratio between methods confirm a statistically significant difference.
CONCLUSION: Blood cortisol levels detected with ECLIA method seems to be higher than the ones measured by LC-MS/MS, indicating a possible overestimation of them in patients treated with PD. Therefore, the cortisol suppression in patients under treatment with oral PD should not be measured using ECLIA method.

Entities:  

Keywords:  Cortisol; Immunoassay; Liquid chromatography; Prednisone; Tandem mass spectrometry; Ulcerative colitis

Mesh:

Substances:

Year:  2014        PMID: 25152591      PMCID: PMC4138468          DOI: 10.3748/wjg.v20.i31.10895

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  9 in total

Review 1.  Measuring agreement in method comparison studies.

Authors:  J M Bland; D G Altman
Journal:  Stat Methods Med Res       Date:  1999-06       Impact factor: 3.021

2.  Conventional RIA underestimates cortisol suppression in the presence of prednisolone.

Authors:  R J Meijer; D S Postma; H A M Kerstjens
Journal:  Thorax       Date:  2002-04       Impact factor: 9.139

3.  Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology.

Authors:  Mark S Silverberg; Jack Satsangi; Tariq Ahmad; Ian D R Arnott; Charles N Bernstein; Steven R Brant; Renzo Caprilli; Jean-Frédéric Colombel; Christoph Gasche; Karel Geboes; Derek P Jewell; Amir Karban; Edward V Loftus; A Salvador Peña; Robert H Riddell; David B Sachar; Stefan Schreiber; A Hillary Steinhart; Stephan R Targan; Severine Vermeire; B F Warren
Journal:  Can J Gastroenterol       Date:  2005-09       Impact factor: 3.522

Review 4.  The diagnosis and investigation of adrenal insufficiency in adults.

Authors:  Ian Wallace; Sean Cunningham; John Lindsay
Journal:  Ann Clin Biochem       Date:  2009-08-12       Impact factor: 2.057

Review 5.  Measurement of salivary cortisol in 2012 - laboratory techniques and clinical indications.

Authors:  Warrick J Inder; Goce Dimeski; Anthony Russell
Journal:  Clin Endocrinol (Oxf)       Date:  2012-11       Impact factor: 3.478

6.  Standardized LC-MS/MS based steroid hormone profile-analysis.

Authors:  Therese Koal; Diane Schmiederer; Hai Pham-Tuan; Cornelia Röhring; Manfred Rauh
Journal:  J Steroid Biochem Mol Biol       Date:  2011-12-27       Impact factor: 4.292

Review 7.  Glucocorticosteroid therapy in inflammatory bowel disease: systematic review and meta-analysis.

Authors:  Alexander C Ford; Charles N Bernstein; Khurram J Khan; Maria T Abreu; John K Marshall; Nicholas J Talley; Paul Moayyedi
Journal:  Am J Gastroenterol       Date:  2011-03-15       Impact factor: 10.864

Review 8.  Comparative tolerability of therapies for ulcerative colitis.

Authors:  Sandro Ardizzone; Gabriele Bianchi Porro
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

9.  Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management.

Authors:  Axel Dignass; James O Lindsay; Andreas Sturm; Alastair Windsor; Jean-Frederic Colombel; Mathieu Allez; Gert D'Haens; André D'Hoore; Gerassimos Mantzaris; Gottfried Novacek; Tom Oresland; Walter Reinisch; Miquel Sans; Eduard Stange; Severine Vermeire; Simon Travis; Gert Van Assche
Journal:  J Crohns Colitis       Date:  2012-10-03       Impact factor: 10.020

  9 in total
  3 in total

1.  Correlation analysis for follicle-stimulating hormone and C-terminal cross-linked telopetides of type i collagen in menopausal transition women with osteoporosis.

Authors:  Bing Wang; Yang Song; Yan Chen; En-Sheng Wang; Dan Zheng; Fan Qu; Jian-Hong Zhou
Journal:  Int J Clin Exp Med       Date:  2015-02-15

2.  Oral prolonged release beclomethasone dipropionate and prednisone in the treatment of active ulcerative colitis: results from a double-blind, randomized, parallel group study.

Authors:  Gert Van Assche; Francesco Manguso; Marco Zibellini; José Luis Cabriada Nuño; Adrian Goldis; Evgeniy Tkachenko; Guido Varoli; Dariusz Kleczkowski; Vito Annese; François D'Heygere; Antonio Balzano
Journal:  Am J Gastroenterol       Date:  2015-04-14       Impact factor: 10.864

Review 3.  Efficacy and Safety of Oral Beclomethasone Dipropionate in Ulcerative Colitis: A Systematic Review and Meta-Analysis.

Authors:  Francesco Manguso; Raffaele Bennato; Giovanni Lombardi; Elisabetta Riccio; Giuseppe Costantino; Walter Fries
Journal:  PLoS One       Date:  2016-11-15       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.